Prof. Dr. Dario Neri (CEO and CSO), Dr. Covelli (CMO), Dr. Dakhel, Dr. De Luca, Dr. Cazzamalli, Dr. Galbiati, Dr. Puca, Matilde Bocci, Eleonora Prodi, Sara Puglioli, Giulia Rotta and Aureliano Zana will participate at the event.
Moreover, the following abstracts have been accepted as Poster Presentations:
Dr. Galbiati – Tumor-targeted interleukin-2 enhances the anti-cancer activity of multivalent OncoFAP radioligand therapeutics
Eleonora Prodi – Tripokin: potential best-in-class for tumor targeted interleukin-2 (IL2) potentiated by tumor necrosis factor (TNF)
Matilde Bocci – Delivery of cytotoxic camptothecin derivatives to tumors by OncoFAP-based Small Molecule-Drug Conjugates
Sara Puglioli – DNA-encoded affinity maturation libraries enable the discovery of low picomolar Fibroblast Activation Protein inhibitors suitable for radioligand therapy of solid tumors
Aureliano Zana – FAP-targeted non-internalizing drug conjugates: a comparative evaluation between small molecules, antibodies and peptides
Giulia Rotta – Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation.
Please follow the link for more information